Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Sintilimab + Regorafenib in CRC Liver Metastasis
NCT05057052Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in colorectal cancer (CRC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05057052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057052.